Anne–Marie Langevin, MD

• Professional Background

  Education

  • 1989 - Clinical Fellowship - Drug Development - University of North Carolina/Burroughs Wellcome
  • 1988 - Clinical Fellowship - Pediatrics Hematology/Oncology - Hospital for Sick Children
  • 1984 - Residency - Adult Hematology - University of Montreal
  • 1982 - Residency - Internal Medicine - University of Montreal
  • 1980 - MD - Medicine - University of Montreal
  • 1975 - Health Science - College Marie-Victorin

  Appointments

  • 12/2014 - Greehey Distinguished Chair in Pediatric Oncology - University of Texas Health Science Center, Pediatrics

• Instruction & Training

  • 2/2017 - Present, Post Graduate Rotation Supervision, UTHSCSA
  • 9/2011 - Present, Pediatric Hematology Oncology Board Didactics, CHRISTUS Santa Rosa Hospital
  • 1/2009 - Present, Post Graduate Rotation Supervision, UTHSCSA/CSRCH/UHS
  • 2/2008 - Present, Hematology-Oncology Journal Club, UTHSCSA
  • 4/2005 - Present, Adult Sarcoma Tumor Board, UTHSCSA
  • 7/2003 - Present, Pediatric Tumor Board, UTHSCSA/CSRCH
  • 6/1999 - Present, Hematology/Oncology #1, The University of Texas Health Science Center
  • 3/1992 - Present, Rotation Student Supervision, UTHSCSA
  • 3/1992 - Present, Post Graduate Rotation Supervision, UTHSCSA

• Research & Grants

  Clinical Trials, Pediatric Cancer, Phase I, Sarcoma

  Population Science and Prevention Program 

  Research profile

  Grants

  Federal

  Funding Agency NCI Title South Texas Pediatric NCORP Status Active Period 8/2014 - 7/2019 Role Principal Investigator Grant Detail The goals of this infrastructure grant are to: 1) Provide the infrastructure necessary to maintain an active NCI-sponsored clinical trial program at the institutional level as well as at three other pediatric oncology program covering central and South Texas; 2) Increase enrollment of minority and underserved populations (i.e. Hispanics and Adolescents and Young Adults) on clinical trials; and 3)Develop an infrastructure system that will support cancer care delivery research.

  Private

  Funding Agency Genentech/MSK Title POETIC (GO29665) Status Active Period 4/2016 - Present Role Principal Investigator Grant Detail Funding Agency Genentech/MSK Title POETIC (GO29664) Status Active Period 10/2015 - Present Role Principal Investigator Grant Detail Funding Agency AMGEN Title POETIC (POE14-01) Status Active Period 4/2016 - Present Role Principal Investigator Grant Detail Funding Agency PUMA Title POETIC (POE16-01) Status Active Period 7/2017 - Present Role Principal Investigator Grant Detail

   

  Funding Agency St. Baldrick's Foundation Title Project Every AYA - Everyone Deserves a Chance Status Active Period 1/2017 - 12/2017 Role Principal Investigator Grant Detail

• Publications

  Abstract

  Lipsitt AE,
  Diaz VR,
  Hung J,
  Weitman S,
  Langevin AM. Complete Remission in a Young Adult with Recurrent Extranodal NK/T-cell Lymphoma Treated on the iMATRIX Early-Phase Open-Label Atezolizumab Trial (GO29664); 2018 Jul. (POETIC Summer Meeting - 2018). Lopez MP,
  Diaz VR,
  Langevin AM. Localized Translation and Real-Time interpretation of Informed Consent Forms in Pediatric Oncology Clinical Trial Participation; 2018 Feb. (Advancing the Science of Cancer in Latinos - Inaugural Meeting San Antonio 2018). Higgerson K,
  Langevin AM,
  Rajani R,
  Heim-Hall J,
  Hung J,
  Sugalski AJ. Characterization of Localized Osteosarcoma of the Extremity in Children, Adolescents, and Young Adults from South Texas: Increasing Insight into Hispanic Populations; 2018 Feb. (Advancing the Science of Cancer in Latinos - Inaugural Meeting San Antonio 2018). Cruz A, Bensal H, Tomlinson M, Bansal S, Langevin AM, Weitman SD. Hydroxychloroquine in Combination with Vorinostat to Improve Response in Pediatric Solid Tumor Cell Lines; 2017 Mar. (POETIC Winter Meeting - 2017). Trippett T, Rossato G, Langevin AM, Michon J, Frappas D, Locatelli F, Kowgler M, Tagen M, Kwan A, Das Thakur M, Georger B. A Phase I/II study of atezolizumab in pediatric and young adult patients with refractory/relapsed solid tumors (iMATRIX-Atezolizumab); 2017 Jan. (49th Annual SIOP Meeting 2017). Hung JY; Heim-Hall J; Chen Y; Langevin AM. MicroRNA signatures in osteosarcoma associated with clinical outcome; 2013 Sep. (Pediatric Blood and Cancer - SIOP 45th Congress).

  Journal Article

  Langevin AR. Risk factors for chemotherapy-induced nausea in pediatric patients receiving highly emetogenic chemotherapy Pediatric Blood and Cancer 2018 Dec;. Dupuis LL
  Kelly KM
  Krischer JP
  Langevin AM
  Tamura RN
  Xu P
  Chen L
  Kolb EA
  Ullrich NJ
  Sahler OJZ
  Hendershot E
  Stratton A
  Sung L
  McLean TW. Acupresure bands do not improve chemotherapy-induced nausea control in pediatric patients receiving highly emetogenic chemotherapy: a single-blinded randomized controlled trial Cancer 2018 Mar;124(6):1188-1196. Joanne P. Lagmay, Mark Krailo, Ha Dang, AeRang Kim, Douglas Hawkins, Mason Bond, Orren Beaty, Brigette Widemann, Ted Zwerdling, Lisa Bomgaars, Anne-Marie Langevin, Holcombe Grier, Brenda Weigel, Richard Gorlick, Katherine Janeway. Outcome of recurrent osteosarcoma patients enrolled in seven phase II trials through CCG, POG, and COG: Learning from the past to move forward Journal of Clinical Oncology 2016 Sep;34(25). Patel Priya
  Robinson, Paula D
  Orsey, Andrea
  Freedman, Jason L
  Langevin AR
  Woods Debbie
  Sung Lillian
  Dupuis Lee. Chemotherapy-Induced Nausea and Vomiting Prophylaxis: Practice Within the Children?s Oncology Group Pediatric Blood and Cancer 2016 May;:1-6. Roth, Michael
  O`Mara, Ann
  Seibel, Nita
  Dickens, David
  Langevin AR
  Pollock, Brad
  Freyer, David. Low Enrollment of Adolescents and Young Adults Onto Cancer Trials: Insights From the Community Clinical Oncology Program Journal of Oncology Practice 2016 Apr;. Bartanusz V, Ziu M, Jimenez DF, Crownover RL, Langevin AM. Zoledronic acid therapy for recurrent giant cell tumor of the C2 vertebra in an adolescent Spine J 2015 Mar;15(8):1886-1887. Patricia C. Sanchez-Diaz, Tzu-Hung Hsiao1, Yi Zou1, Aaron J. Sugalski, Josefine Heim-Hall, Yidong Chen, Anne-Marie Langevin, Jaclyn Y. Hung1. In silico functional analyses and discovery of survival-associated microRNA signatures in pediatric osteosarcoma Oncoscience 2014 Sep;.

• Clinical

  Board Certifications

  • American Board of Pediatrics/Hematology-Oncology